MyOme
MyOme is a genomics company in Menlo Park, California, with a CLIA certified and CAP accredited laboratory, that sells whole genome screening built around integrated risk scores. Its MyOme Atlas tests cover a curated screen of genes with actionable findings, medication response, cardiometabolic risk and cancer risk. The risk results come from integrated polygenic risk scores that combine common variant scores with rare variants and clinical factors and are validated across ancestries. Since December 2024 MyOme has also computed the breast cancer risk score offered with Natera's Empower hereditary cancer test to women whose panel is negative, and it powers Natera Zenith, Natera's rare disease genome and exome tests.
MyOme sells to clinicians, employers, health systems and benefits consultants, with partnerships including Collective Health and Thatch for employers. Since September 2026 its platform and testing services have run on Oracle Cloud Infrastructure and are offered worldwide, with MyOme in the Oracle PartnerNetwork. For rare disease it adds long read methylation analysis, launched in March 2026, and in November 2026 it licensed DNA methylation signatures developed at SickKids. Its breast cancer model, published in JCO Precision Oncology in 2023 and validated in the Women's Health Initiative and UK Biobank, improved on the Tyrer-Cuzick clinical model in every ancestry group reported, with published figures for Hispanic and White women. Coronary artery disease work followed in npj Cardiovascular Health (2025) and the American Journal of Preventive Cardiology (2026).
Illumina made a strategic investment in December 2025 to support the MyOme Proactive Health trial, a prospective study of whole genome screening with integrated risk models for chronic disease, cancer and rare disease, enrolling from 2026. No outcome results are published yet, and no price is published. MyOme publishes a HIPAA notice that sets out when it acts as a covered entity and when customer data is governed by business associate agreements.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
The risk modules run on models, and the genome carries other value. MyOme's cardiometabolic and cancer results are integrated risk scores, models fitted to population data that combine a cross ancestry polygenic score with rare variants and clinical factors, and those modules do not exist without them. MyOme describes its approach as whole genome sequencing, advanced bioinformatics and AI.
The same genome also yields a curated screen of genes with actionable findings and medication response results, which are laboratory interpretation rather than model output, and MyOme's rare disease work for Natera is diagnostic sequencing. Without the models, a genome screening service remains.
Results reach an ordering clinician, and the controls around the scores are not described. MyOme tests are ordered through clinicians and returned as a report, so a person accountable for the patient decides what to do with a risk estimate.
Nothing published says who reviews a risk score before release, when a score is withheld, for example for ancestries or ages outside validation, how scores are presented against clinical thresholds, or how an updated model changes a result already issued.
The approach is named without version and update discipline. MyOme describes integrated risk models that combine a cross ancestry polygenic risk score, rare variants and clinical factors such as those in Tyrer-Cuzick, and its breast cancer paper names the development cohorts and the validation design. Sequencing uses Illumina technology and runs from whole genomes.
No model version is published, and nothing describes how models are recalibrated or how a customer learns that a score's method changed.
The model chain is in house and short. MyOme builds and runs its own integrated risk models in its own laboratory, with no outside model provider named or implied, and MyOme computes the breast cancer score it supplies to Natera's Empower customers. Illumina supplies sequencing technology, and Oracle Cloud Infrastructure runs the platform and testing services, which makes Oracle the named host.
MyOme's notice says customer data is governed by business associate agreements and that de identified data may go to third parties, without naming processors, and no subprocessor list is published.
Peer reviewed validation of risk prediction, and the outcome claims are still being tested. The breast cancer model was published in JCO Precision Oncology (2023): developed on 10,927 cases and 114,390 controls from UK Biobank, the Multiethnic Cohort and an African diaspora study, and validated in the Women's Health Initiative (25,284 women) and the remaining UK Biobank participants (119,187 women). Against Tyrer-Cuzick alone, the odds ratio per standard deviation for remaining lifetime risk rose from 1.31 to 1.88 in Hispanic women and from 1.29 to 1.78 in White women, area under the curve rose from 0.58 to 0.68 and from 0.57 to 0.66, and the score was well calibrated across deciles in every self reported ancestry group. Coronary artery disease models are published in npj Cardiovascular Health (2025) and the American Journal of Preventive Cardiology (2026). The authors include MyOme and Natera staff.
MyOme's headline claims are about lifelong benefit and cost savings, which these studies do not test; the prospective MyOme Proactive Health trial, enrolling from 2026, is meant to.
A consent commitment is stated and the downstream use of de identified data is broad. MyOme's notice says it will never use protected health information for research without consent, and that it may create de identified or aggregated information for research, internal analysis, analytics and publications and make it available to third parties. No retention period for samples or genome data is stated, no de identification method is named, and nothing says whether customer genomes are used to train or recalibrate the risk models.
A whole genome is among the hardest data to de identify, which makes the third party use clause the first thing to clarify. Safety engineering for the risk models, meaning how a faulty score would be detected and handled, is not published.
Both roles are stated, and the agreement is not published. MyOme's HIPAA Notice of Privacy Practices, effective February 2025, says MyOme uses and discloses protected health information when it acts as a covered entity, and that customer protected health information is governed by the business associate agreements it has in place with customers rather than by the notice. The notice describes patient rights, including correction, and says MyOme will never use protected health information for research without consent.
The business associate agreement offered to employers and health systems is not published, and the notice does not say which programs fall under which role.
Nothing independent is published. MyOme displays a HIPAA compliance badge, which is a compliance claim rather than an audit of how it runs security, and no SOC 2 report, HITRUST certification, ISO/IEC 27001 certificate, penetration testing statement or trust center is published. Laboratory accreditation covers testing quality rather than information security.
The company holds whole genomes for screening programs run for employers and health systems.
No device claim is made, and the scores are delivered as laboratory results. MyOme describes a CLIA certified and CAP accredited laboratory, and its tests and risk scores are reported from it on a clinician's order. No FDA clearance is claimed for any test or model, and no regulatory position for the integrated risk scores is published.
Results are compared across ancestry groups for the breast cancer model, with numbers. Polygenic scores typically lose accuracy outside European ancestry, and MyOme's model was built to address that: developed on cohorts including the Multiethnic Cohort and an African diaspora study, and validated by self reported ancestry in the Women's Health Initiative and UK Biobank (JCO Precision Oncology, 2023). The paper reports the odds ratio per standard deviation and area under the curve by group, for example 1.88 and 0.68 in Hispanic women against 1.78 and 0.66 in White women in the respective cohorts, says the score was well calibrated in every self reported ancestry group, and MyOme reports twice as many high risk Black women identified as with Tyrer-Cuzick alone. Figures for Black women sit in the paper's supplement.
The coronary artery disease models carry cross ancestry work in a poster and papers whose group results are not set out on MyOme's pages.
MyOme acts as a covered entity for the results it reports, the risk score is part of that result, and its notice gives the patient a correction route against MyOme directly. The notice says patients can ask MyOme to correct information they think is incorrect or incomplete, and that MyOme will explain any refusal in writing within 60 days.
No error rate is published for the risk scores at the thresholds that change care, and no warranty, indemnity or reissue commitment attaches to a score.
Integration is offered through partners, with no record system MyOme itself documents. MyOme has joined the Oracle PartnerNetwork to reach healthcare organizations through the Oracle Marketplace, without describing a record integration or a live site. Its breast cancer score reaches clinicians inside Natera's Empower hereditary cancer report, and Zenith reaches them through Natera's record integrations, both ordered and returned by Natera, and MyOme tests are offered inside record workflows through Nest Genomics, a separate company's product.
No integration page, standard or named health system is published by MyOme.
A single hosted service on a named cloud, with location not committed. MyOme sequences in its own accredited laboratory in the United States and returns results by report, and its September 2026 release says its platform and testing services run on Oracle Cloud Infrastructure and are now available worldwide. Nothing published says in which regions genomes are stored or processed, whether processing for international customers happens outside the United States, or how customers are kept apart.
No price is published and how the product is sold can be established. MyOme sells MyOme Atlas tests through clinicians, to employers and benefits consultants, including through a partnership with Collective Health, and to health systems, and supplies the genome behind Natera's Zenith rare disease tests. The site offers routes for patients, providers and employers without a price, a unit of charge or an insurance position.
Coverage is named with validation behind part of it. Integrated risk scores are validated across ancestries for breast cancer and coronary artery disease, with type 2 diabetes work presented as a poster. MyOme Atlas also covers medication response and a curated screen of actionable genes, and MyOme describes risk models for kidney, liver and cognitive conditions and other cancers in its December 2025 release, without published validation for those.
The Atlas tests are offered to adults through clinicians, employers and health systems for proactive screening, rather than to people with symptoms. Zenith covers rare disease genome, exome and copy number testing, with long read methylation analysis added in 2026, and MyOme runs a no charge cascade testing program for relatives of people with autosomal dominant hypocalcemia type 1.
Alternatives to MyOme
Other products that do the same kind of work as MyOme, and what each one does.
Allelica, based in San Francisco, builds polygenic risk scores and sells them several ways.
Ambry Genetics is a genetic testing laboratory in Aliso Viejo, California, founded in 1999 and owned since 2025 by Tempus AI.
Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories.
Genomics trades as Genomics and is registered in England as Genomics Ltd, formerly Genomics plc. Its US arm, Genomics Inc., is wholly owned by Genomics Ltd.
Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.
Rare disease genomic diagnosis company (NASDAQ: WGS) in Gaithersburg, Maryland, running exome and genome sequencing in its own accredited laboratory and interpreting it with automation, machine learning and clinical scientists over GeneDx Infinity, its dataset of prior cases.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published
|
Whole genome screening tests ordered through clinicians and sold to employers, benefits consultants and health systems; no unit of charge published. | Covered entity for results it reports; customer data governed by business associate agreements, which are not published. | Not published. | Vendor Published |
MyOme's site offers routes for patients, providers, employers and health systems, and names a Collective Health partnership for employers, without a price, unit of charge or insurance position. The breast cancer score supplied with Natera's Empower test and the Natera Zenith tests are sold by Natera on its own terms.